COSCIENS Biopharma Valuation
| CSCI Stock | 3.13 0.04 1.29% |
At this time, the firm appears to be overvalued. COSCIENS Biopharma shows a prevailing Real Value of USD2.83 per share. The current price of the firm is USD3.13. Our model approximates the value of COSCIENS Biopharma from analyzing the firm fundamentals such as return on equity of -0.66, and Operating Margin of (1.61) % as well as examining its technical indicators and probability of bankruptcy.
Price Book 0.4942 | Enterprise Value -13 M | Enterprise Value Ebitda 3.3303 | Price Sales 2.6615 | Enterprise Value Revenue 2.6735 |
Overvalued
Today
Please note that COSCIENS Biopharma's price fluctuation is unstable at this time. Calculation of the real value of COSCIENS Biopharma is based on 3 months time horizon. Increasing COSCIENS Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since COSCIENS Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of COSCIENS Stock. However, COSCIENS Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.13 | Real 2.83 | Hype 3.16 | Naive 3.34 |
The intrinsic value of COSCIENS Biopharma's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence COSCIENS Biopharma's stock price.
Estimating the potential upside or downside of COSCIENS Biopharma helps investors to forecast how COSCIENS stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of COSCIENS Biopharma more accurately as focusing exclusively on COSCIENS Biopharma's fundamentals will not take into account other important factors: COSCIENS Biopharma Cash |
|
COSCIENS Biopharma Total Value Analysis
COSCIENS Biopharma is currently forecasted to have valuation of (13.04 M) with market capitalization of 13.08 M, debt of 3.59 M, and cash on hands of . The negative valuation of COSCIENS Biopharma may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the COSCIENS Biopharma fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(13.04 M) | 13.08 M | 3.59 M |
COSCIENS Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. COSCIENS Biopharma has an asset utilization ratio of 23.09 percent. This signifies that the Company is making USD0.23 for each dollar of assets. An increasing asset utilization means that COSCIENS Biopharma is more efficient with each dollar of assets it utilizes for everyday operations.COSCIENS Biopharma Ownership Allocation
The market capitalization of COSCIENS Biopharma is USD13.08 Million. Almost 91.99 percent of COSCIENS Biopharma outstanding shares are held by general public with 1.32 (percent) owned by insiders and only 6.69 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.COSCIENS Biopharma Profitability Analysis
The company reported the previous year's revenue of 7.26 M. Net Loss for the year was (3.55 M) with profit before overhead, payroll, taxes, and interest of 0.About COSCIENS Biopharma Valuation
An absolute valuation paradigm, as applied to COSCIENS Stock, attempts to find the value of COSCIENS Biopharma based on its fundamental and basic technical indicators. By analyzing COSCIENS Biopharma's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of COSCIENS Biopharma's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of COSCIENS Biopharma. We calculate exposure to COSCIENS Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of COSCIENS Biopharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 3 M | 5.1 M |
COSCIENS Biopharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 78.3 M |
Complementary Tools for COSCIENS Stock analysis
When running COSCIENS Biopharma's price analysis, check to measure COSCIENS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy COSCIENS Biopharma is operating at the current time. Most of COSCIENS Biopharma's value examination focuses on studying past and present price action to predict the probability of COSCIENS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move COSCIENS Biopharma's price. Additionally, you may evaluate how the addition of COSCIENS Biopharma to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |